Epoprostenol (Veletri®)

Assessment Status Rapid review complete
Drug Epoprostenol
Brand Veletri®
Indication For the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH associated with connective tissue diseases) in patients with WHO FC III–IV symptoms to improve exercise capacity
Assessment Process
Rapid review commissioned 13/12/2016
Rapid review completed 06/02/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Not Recommended